These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 29209226)

  • 1. Uncertainty Quantification Reveals the Importance of Data Variability and Experimental Design Considerations for
    Chang KC; Dutta S; Mirams GR; Beattie KA; Sheng J; Tran PN; Wu M; Wu WW; Colatsky T; Strauss DG; Li Z
    Front Physiol; 2017; 8():917. PubMed ID: 29209226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of an
    Dutta S; Chang KC; Beattie KA; Sheng J; Tran PN; Wu WW; Wu M; Strauss DG; Colatsky T; Li Z
    Front Physiol; 2017; 8():616. PubMed ID: 28878692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving prediction of torsadogenic risk in the CiPA in silico model by appropriately accounting for clinical exposure.
    Leishman DJ
    J Pharmacol Toxicol Methods; 2020; 101():106654. PubMed ID: 31730936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Introduction to
    Park JS; Jeon JY; Yang JH; Kim MG
    Transl Clin Pharmacol; 2019 Mar; 27(1):12-18. PubMed ID: 32055576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac voltage-gated ion channels in safety pharmacology: Review of the landscape leading to the CiPA initiative.
    Huang H; Pugsley MK; Fermini B; Curtis MJ; Koerner J; Accardi M; Authier S
    J Pharmacol Toxicol Methods; 2017 Sep; 87():11-23. PubMed ID: 28408211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico assessment on TdP risks of drug combinations under CiPA paradigm.
    Qauli AI; Marcellinus A; Setiawan MA; Zain AFN; Pinandito AM; Lim KM
    Sci Rep; 2023 Feb; 13(1):2924. PubMed ID: 36807374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global Sensitivity Analysis of Ventricular Myocyte Model-Derived Metrics for Proarrhythmic Risk Assessment.
    Parikh J; Di Achille P; Kozloski J; Gurev V
    Front Pharmacol; 2019; 10():1054. PubMed ID: 31680938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving the In Silico Assessment of Proarrhythmia Risk by Combining hERG (Human Ether-à-go-go-Related Gene) Channel-Drug Binding Kinetics and Multichannel Pharmacology.
    Li Z; Dutta S; Sheng J; Tran PN; Wu W; Chang K; Mdluli T; Strauss DG; Colatsky T
    Circ Arrhythm Electrophysiol; 2017 Feb; 10(2):e004628. PubMed ID: 28202629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. qInward variability-based
    Jeong DU; Qashri Mahardika T N; Marcellinus A; Lim KM
    Front Physiol; 2022; 13():1080190. PubMed ID: 36589462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving regulatory paradigm for proarrhythmic risk assessment for new drugs.
    Vicente J; Stockbridge N; Strauss DG
    J Electrocardiol; 2016; 49(6):837-842. PubMed ID: 27524478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of Bnet, a Simple Linear Metric in Discerning Torsades De Pointes Risks in 28 CiPA Drugs.
    Han S; Han S; Kim KS; Lee HA; Yim DS
    Front Pharmacol; 2019; 10():1419. PubMed ID: 31849669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of Normalized TdP Score System in Drug Proarrhythmic Potential Assessment: A Blinded in vitro Study of CiPA Drugs.
    Liu T; Liu J; Lu HR; Li H; Gallacher DJ; Chaudhary K; Wang Y; Yan GX
    Clin Pharmacol Ther; 2021 Jun; 109(6):1606-1617. PubMed ID: 33283267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel.
    Crumb WJ; Vicente J; Johannesen L; Strauss DG
    J Pharmacol Toxicol Methods; 2016; 81():251-62. PubMed ID: 27060526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive in vitro Proarrhythmia Assay, a novel in vitro/in silico paradigm to detect ventricular proarrhythmic liability: a visionary 21st century initiative.
    Cavero I; Holzgrefe H
    Expert Opin Drug Saf; 2014 Jun; 13(6):745-58. PubMed ID: 24845945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blinded
    Zhou X; Qu Y; Passini E; Bueno-Orovio A; Liu Y; Vargas HM; Rodriguez B
    Front Pharmacol; 2019; 10():1643. PubMed ID: 32082155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-Dimensional Heart Model-Based Screening of Proarrhythmic Potential by
    Hwang M; Han S; Park MC; Leem CH; Shim EB; Yim DS
    Front Physiol; 2019; 10():1139. PubMed ID: 31551815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proarrhythmic risk assessment of drugs by dV
    Jeong DU; Yoo Y; Marcellinus A; Kim KS; Lim KM
    CPT Pharmacometrics Syst Pharmacol; 2022 May; 11(5):653-664. PubMed ID: 35579100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proarrhythmia liability assessment and the comprehensive in vitro Proarrhythmia Assay (CiPA): An industry survey on current practice.
    Authier S; Pugsley MK; Koerner JE; Fermini B; Redfern WS; Valentin JP; Vargas HM; Leishman DJ; Correll K; Curtis MJ
    J Pharmacol Toxicol Methods; 2017 Jul; 86():34-43. PubMed ID: 28223123
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Hwang M; Lim CH; Leem CH; Shim EB
    APL Bioeng; 2020 Jun; 4(2):021502. PubMed ID: 32548538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the CiPA Initiative.
    Li Z; Ridder BJ; Han X; Wu WW; Sheng J; Tran PN; Wu M; Randolph A; Johnstone RH; Mirams GR; Kuryshev Y; Kramer J; Wu C; Crumb WJ; Strauss DG
    Clin Pharmacol Ther; 2019 Feb; 105(2):466-475. PubMed ID: 30151907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.